Effectiveness of Colchicine for the Treatment of Long COVID

作者：Abhinav Bassi, Niveditha Devasenapathy, Shani S. Thankachen, Arpita Ghosh, Aman Rastogi, Ritika Khan, Bijini Bahuleyan, Balaji Gummidi, Aneesh Basheer, Thekkumkara Prabhakaran Sreelal, Ashfak Bangi, Yasmeen Shaikh, Dibakar Sahu, Vinay Rathore, Ashish Bhalla, Samita Samita, Merlin Blessan, T. S. Dipu, Manish Jain, Abhishek Prajapati, Narendra Kuber Bodhey, Vivekanand Jha · 发表于：JAMA Internal Medicine · 年份：2025 · DOI：10.1001/jamainternmed.2025.5408 · 被引用次数：5 · 研究领域：Long-Term Effects of COVID-19、Inflammasome and immune disorders、COVID-19 Clinical Research Studies

Importance: Long COVID is characterized by persistent symptoms after SARS-CoV-2 infection, with inflammation playing a key role in pathogenesis. Colchicine, an established anti-inflammatory agent, may reduce these symptoms by targeting inflammatory pathways. Objective: To evaluate the superiority of colchicine over placebo in improving functional outcome at 52 weeks from baseline. Design, Setting, and Participants: This double-blind, 1:1 randomized clinical trial recruited participants with confirmed SARS-CoV-2 infection and persistent symptoms from 8 hospitals in 6 states in India between January 2022 and July 2023. Individuals were eligible if they had functional limitation (Post-COVID-19 Functional Status scale grade 2 or more) and/or elevated inflammatory markers (high-sensitivity C-reactive protein >0.20 mg/dL and/or neutrophil to lymphocyte ratio >5). Outcomes were assessed at 12, 26, and 52 weeks after randomization. Data were analyzed from January to February 2025. Interventions: Participants were randomly assigned to receive colchicine, 0.5 mg, once or twice daily, based on body weight, or placebo for 26 weeks. Main Outcomes and Measures: The primary outcome was the change in distance walked during a 6-minute walk test from baseline to 52 weeks. Secondary outcomes included changes in inflammatory markers and patient-reported outcome measures, such as quality of life, anxiety, depression, fatigue, dyspnea, measured using validated instruments. Results: Of 346 particip...